01 / PEPTIDES
Peptide payment processing, without the guesswork.
We match peptide sellers with high-risk payment processors whose underwriting actually fits the business - the product, the end-use framing, the geography, the checkout. Then we walk you through the application, the pricing, the reserve and the contract terms.
A peptide merchant account is not a retail account with a different label on it. It gets underwritten by a processor with a written peptide policy and an acquiring bank willing to board the category, and the price depends mostly on how the business reads on the page.
Free to use · Team responds ASAP · We’re paid by the processor, not you.
The short version
- Peptides are high risk for one structural reason: the same vial can be sold as a lab reference material or implied as a human-use drug, and banks price those two businesses very differently.
- High-risk payment processors for peptides typically quote card rates of 3% to 8.95%, ACH at 3.95% flat, and a rolling reserve of 5% to 10% held for 90 to 180 days.
- The biggest lever you control is how the business reads on the page - research-use-only framing, no dosing guides, no before-and-after photos, no therapeutic claims.
- Most peptide sellers are placed under MCC 5499, 5912 or 5999. The code tells the acquirer what kind of risk it just boarded, and it shapes pricing and monitoring.
- Documentation decides the outcome: entity papers, EIN, bank statements, supplier sourcing, product listings, and a marketing review.
- Some processors require LegitScript certification for peptide merchants. Some waive it for research-only sellers with clean documentation.
- We’re free to use. We’re paid by the processor when a merchant we match starts processing.
02 / WHY PEPTIDES GET DECLINED
Why peptide sellers get declined.
Most peptide merchants who get turned down assume the problem is the product. It usually isn’t. It’s end-use ambiguity - and it shows up in the same three places every time.
Underwriting has one job on a peptide file: decide what the customer does with the product after it ships. Everything else - volume, average ticket, chargeback history - is secondary to that answer. A clean $80,000-a-month store with no clear end use is harder to board than a $400,000-a-month store that can prove every order is a lab purchase.
Unclear end use. If a product page says “Tirzepatide 10mg” and nothing else, the underwriter has to guess who is buying it and why. Guessing is expensive, so the file stops. A peptide business that can describe a coherent customer - research labs, universities, contract research organisations, a named B2B segment - gets a different conversation than one where the buyer could plausibly be someone self-administering at home.
Overlap with human consumption. Product formats give this away faster than copy does. Lyophilised vials paired with bacteriostatic water, insulin-style pens, pre-filled syringes, nasal spray bottles, capsules sold in 30-day counts. Each one is a legitimate lab format in isolation. Together, they describe a consumer dosing regimen. Underwriting reads the pattern, not the individual item.
Marketing language that implies therapeutic benefit. Weight loss, recovery, healing, anti-aging, “cycle,” “stack,” before-and-after photos, testimonials about sleep or libido. The processor doesn’t have to decide whether a claim is legally permissible. It only has to decide whether the claim makes the merchant look like it is selling a drug. If it does, the answer is a decline or a price that reflects drug-adjacent risk.
The decline reasons we see most often:
- 01
The processor has no peptide policy. The website says “high risk.” The acquiring bank underneath it has never boarded a peptide merchant and won’t start with yours. The application dies at the bank, not at the processor.
- 02
The marketing contradicts the disclaimer. “Research use only” in the footer, a dosing chart in the middle of the page. Underwriting reads both and believes the second one.
- 03
The product mix includes formats the acquirer won’t board. Many processors will look at capsules or topicals and stop at injectables or nasal sprays. You find that out before you apply, or you find it out three weeks in.
- 04
Health claims are sitting where the merchant forgot to look. Meta descriptions, blog posts, ad copy, an abandoned affiliate page, a testimonial page from two years ago. Underwriting finds them.
- 05
Chargeback history that surfaced during underwriting. It should have been disclosed upfront. Rate is arguable. Concealment isn’t.
- 06
The wrong application. The merchant applied to a mainstream processor or a bank first, got declined, and now carries a decline on record with no explanation attached to it.
None of these are permanent. Most are a documentation problem, an application problem, or both.
Find my processor ↗03 / RUO VS HUMAN USE
Research-use-only vs human-use: the distinction that decides everything.
This is the section that matters. If you understand nothing else about peptide payment processing, understand this one.
“Research-use-only” is a labelling and intended-use convention, not a legal category that protects you from anything. It tells the buyer, and the bank, that the product is not intended for human or veterinary use. What it changes is the underwriting model.
A seller framed as RUO gets priced as a specialty retail or laboratory supply merchant. A seller framed as human use gets priced as a drug distributor - if it gets boarded at all. Same molecule, same website platform, same volume. Different risk class, different rate, different reserve, different answer.
Why underwriting treats the two differently. A lab supply merchant sells to a defined, verifiable customer type. Orders are bulk, repeat, and tied to institutions. Disputes are rare because the buyer isn’t evaluating a personal outcome. A human-use seller carries the risk profile of a pharmaceutical business: adverse-event complaints, subscription churn, “it didn’t work” chargebacks, regulatory attention, and a card network that may decide the category doesn’t belong on the rails. That’s the gap processors are pricing. It has very little to do with the chemistry.
How a site reads as human use to an underwriter. Underwriting usually opens your homepage, a product page, a blog post and your checkout, in that order. Human-use signals are cumulative. Two or three of these on a site will outweigh any disclaimer:
- Dosing guidance - mg/kg charts, “how to reconstitute,” injection-frequency tables, a dosing calculator.
- Before-and-after photos, physique photos, progress logs, video reviews.
- Outcome testimonials that reference fat loss, recovery time, sleep, libido, joint pain or energy.
- Bundles named after outcomes rather than compounds - “summer stack,” “recovery protocol.”
- Comparison pages that name prescription drugs by brand and position your product as an alternative.
- Injection supplies sold alongside vials: syringes, needles, alcohol swabs, sterile water.
- Support content that answers “how much should I take” instead of “what’s the lot purity.”
- A consumer checkout: single-vial retail quantities, discount codes, an abandoned-cart email sequence pushing urgency.
Any one of those is survivable. Five of them on one site is a human-use business wearing an RUO label, and underwriters are trained to notice exactly that.
What actually supports an RUO position. Documentation is the difference between claiming a research frame and being able to defend one:
- A certificate of analysis for every lot, with the testing lab named, the method listed (HPLC, mass spectrometry), and a lot number the buyer can match to the product.
- “Not for human or veterinary use” appearing consistently - site-wide disclaimer, every product page, packing slip, invoice, and the label itself. Consistency is the point.
- Specification-first product pages. Compound, molecular formula, purity percentage, form, storage conditions. Not benefits.
- Product naming by compound and quantity, not by outcome.
- A COA lookup, searchable by lot number.
- Terms of sale that require the buyer to attest to research use at checkout.
- A B2B ordering pattern - larger quantities, repeat institutional buyers, net terms, purchase orders.
- Supplier documentation with a named manufacturer, so underwriting can see where the product comes from and who stands behind it.
One thing worth saying plainly: the Food and Drug Administration has rejected the idea that an RUO label is a shield by itself. In a December 10, 2024 warning letter to Summit Research Peptides, the agency said the products were unapproved new drugs and specifically discounted the “research use only” and “research chemical only” language in view of how the products were marketed. That is a regulatory case, not a payments case - but processors read the same public record, and so should you.
This is general information about how underwriting works, not legal or medical advice. If you need a view on your own claims or product classification, that’s a lawyer’s job, not a payment advisor’s.
04 / UNDERWRITING
What processors actually look at.
Seven things decide a peptide application. Everything else is noise.
01MCC codes - 5499, 5912, 5999
The merchant category code is how the card networks and the acquirer categorise what you sell. 5499 is a miscellaneous food and specialty retail code, used by some processors as a catch-all for consumable products. 5912 covers drug stores and pharmacies under Visa’s merchant data standards, which puts a peptide merchant in a healthcare-shaped risk bucket. 5999 is miscellaneous and specialty retail; Visa’s Merchant Data Standards Manual says a miscellaneous code should be used only when no more specific code applies. The code drives network-level monitoring and fee treatment. If yours says pharmacy, expect pharmacy-level scrutiny even if your business is a lab supplier. Ask, in writing, which MCC a processor intends to register for you.
02Chargeback thresholds
Processors set their own chargeback tolerance, and for peptides it usually sits between 0.9% and 1.5% - tighter than the card network’s own excessive levels. Visa’s Acquirer Monitoring Program fact sheet lists acquirer portfolio levels beginning at 50 basis points, with merchant excessive thresholds set to tighten further from April 2026. A processor is not going to let your file push its portfolio into a monitoring programme.
03Product documentation
Certificates of analysis, lot numbers, purity, testing method, the name of the lab that ran the panel. Underwriting wants to know that you know what’s in the vial. Merchants with lot-level documentation get boarded faster and priced lower than merchants who send a supplier PDF with the logo cropped off.
04Supplier sourcing
Who manufactures the product, in which country, and can you produce invoices that match your COAs. Domestic, named suppliers are the easiest file. Unnamed overseas sourcing with no paper trail is the hardest. If you import, underwriting will ask for customs or shipping documentation as well.
05Marketing claims
Underwriting reads your website the way an investigator would - product pages, blog, about page, FAQ, ad copy, and sometimes your social profiles. The FTC’s Health Products Compliance Guidance sets out the advertiser’s obligation to substantiate objective health claims with competent and reliable scientific evidence, and it applies to implied claims, testimonials and the overall impression of a page - not just the sentence with the claim in it.
06Geography
Where you’re incorporated, where your bank account sits, where you ship, and which states or countries you exclude. Domestic-only shipping with a documented footprint prices better than worldwide shipping from a single-page store. International card traffic on a US peptide merchant is one of the fastest ways to get a reserve placed on your account.
07Product formats
Does the business sell capsules, injectables, nasal sprays, or all three? This single answer narrows the field faster than anything else in the file. Capsules and topicals travel through many programmes. Injectables travel through few. Nasal sprays and anything requiring reconstitution supplies sit in between, and the acquirer’s comfort usually depends on how clean the rest of the file looks.
05 / RATES AND RESERVES
What peptide processing actually costs.
These are the ranges we see across peptide placements. Your number depends on the seven factors above - treat this as a benchmark to sanity-check a quote against, not a price list. Nothing here is an offer or a quote.
The spread is wide because the files are different. A research-only seller with lot-level COAs, domestic sourcing and a clean six-month statement can sit near the bottom of the card range. The same seller adding injectables, running international traffic and carrying a 1.4% chargeback ratio will land at the top of it. The rate is a summary of your risk file, not a market price for “peptides.”
A quote below 3% for a peptide business usually means the processor hasn’t underwritten the vertical properly. It shows up later - as a mid-contract rate review, a sudden reserve, a held payout, or a shutdown notice. Ask any processor quoting the bottom of the range what their peptide chargeback tolerance is, and get the reserve terms in writing before you sign.
Peptide processing also carries costs that don’t appear in the headline rate: gateway and platform fees, per-batch settlement charges, monthly minimums, PCI fees, and specialty merchant fees passed through by the networks. Ask for a full statement rather than a rate. We covered the line items worth arguing about in our notes on specialty merchant fees.
Find my processor ↗06 / LEGITSCRIPT
LegitScript and the certification question.
LegitScript is a certification and monitoring company that payment providers use to verify that a healthcare-adjacent merchant is legitimate. Its healthcare merchant certification confirms things like business identity, licensing, and whether the site’s practices meet a programme’s standards - and payment companies use that verification as a shortcut in their own underwriting.
When a processor requires it. Two situations usually trigger the requirement. The first is regulatory. Visa and Mastercard require certain pharmacy and telehealth merchants to be certified and monitored by an approved organisation, and LegitScript is one recognised provider. That applies largely to merchants processing under pharmacy-shaped categories, MCC 5912 among them. A peptide site registered under 5912 can be pulled into that requirement even if its actual business is lab supply.
The second is the processor’s own policy. An acquiring bank can require certification for any healthcare-adjacent merchant it boards, or make it a condition of approval. That’s a commercial decision, not a network rule, and it varies from processor to processor - some peptide programmes have required it since early 2024, and others never ask.
Why research-only sellers are sometimes exempt. Certification programmes are built for merchants serving patients: pharmacies filling prescriptions, telehealth platforms connecting people to clinicians. A business that sells exclusively to laboratories, makes no human-use claims, publishes COAs and refuses consumer framing doesn’t sit neatly inside that scope. Some processors therefore waive certification for documented research-only sellers, and a few use certification as the alternative to a monthly volume minimum. “Some” is doing real work in that sentence. The waiver is a processor decision, not an entitlement, and it can be withdrawn if your site stops reading as research-only.
What to do about it. Ask before you apply, in writing:
- Is LegitScript certification required for my business, and under which programme?
- If it’s required, does it need to be in place before underwriting, or can the application run while certification is pending?
- If it isn’t required, is that a programme rule or a stated exception for research-only sellers - and does the exception survive a product-mix change?
Certification is neither free nor instant, and the cost and timeline depend on the programme and the merchant. Budget weeks, not days, and build it into your launch plan rather than discovering it mid-underwriting. LegitScript publishes its own certification FAQ if you want the source document.
This is general information about how merchant certification works. It isn’t legal advice and it isn’t medical advice.
07 / BEFORE YOU APPLY
Marketing language is underwriting evidence.
Here’s the part most peptide merchants get wrong: they treat underwriting as a paperwork exercise and their website as marketing. Underwriting treats the website as evidence.
Your product pages, blog posts, FAQ, testimonials, meta titles, ad copy, and even old affiliate pages are read as a description of intended use. A dosing guide is a statement that a human will take the product. A testimonial about weight loss is a claim about a human outcome. A “not for human consumption” banner in the footer doesn’t neutralise a page that contradicts it 400 pixels above.
The pre-application pass. Do this before you submit anything. It takes a day and it changes outcomes more than any negotiation on rate.
- 01
Move the research-use-only statement above the fold on every product page - not just the footer, not just the terms.
- 02
Delete dosing information. Reconstitution guides, mg/kg tables, frequency charts, calculators. All of it.
- 03
Remove before-and-after imagery and physique photos. Including the ones in review sections and image galleries.
- 04
Strip outcome testimonials. Any review that references a health result, a body change, or a symptom is a liability on a peptide file.
- 05
Rename outcome bundles. “Recovery protocol” becomes the compound names and quantities in it.
- 06
Rewrite benefit copy as specification copy. Molecular weight, purity, form, storage, CAS number.
- 07
Publish COAs and make them findable by lot number. This is the single strongest document you can put in front of an underwriter.
- 08
Add a research-use attestation at checkout and record it against the order.
- 09
Clean the metadata. Meta titles and descriptions, ad copy, and email flows get read too - an abandoned-cart email promising results is a claim.
- 10
Review comparison pages and support content. If a page names a prescription drug as an alternative, or a support answer tells someone how much to take, fix it before underwriting finds it.
Every one of these changes moves your file toward “specialty retail” and away from “drug distribution.” That’s the difference between a card rate near the bottom of the 3% to 8.95% range and one near the top. Merchants who do this pass get boarded faster, priced lower, and hit with fewer follow-up requests three months in - because the site they described to underwriting is the site underwriting can still see.
08 / HOW IT WORKS
How the application works.
Six steps, usually two to four weeks end to end if the paperwork is ready. The variable is documentation, not the processor.
- 1
Pre-application review - 1 to 2 days.
We read the site, the product mix, the formats, the geography and the processing history, and tell you what an underwriter will flag before anyone submits anything. This is where most declines get prevented.
- 2
Documentation pack - 2 to 5 days.
You assemble the papers listed below, plus a screenshot set of the marketing pages as they’ll appear at submission.
- 3
Matching and submission - same day to 2 days.
We send you two to four processors whose acquiring bank actually boards your product type, in your states, at your volume. You submit one or two applications - not ten. Every application you file creates a record, and a cluster of simultaneous applications reads as distress.
- 4
Underwriting - 3 to 10 business days.
The processor reviews the file, often asks for one round of clarifications, and may run a site review against the marketing pages you submitted. Answer requests the same day. Files that stall usually stall because the merchant went quiet, not because the processor said no.
- 5
Approval, MID and integration - 1 to 5 business days.
You get a merchant ID, gateway credentials, and a settlement schedule. Test a transaction end to end before you announce anything, and confirm where the rolling reserve appears on your first statement so it isn’t a surprise on day one.
- 6
First settlement and reserve review - 30 to 90 days.
Your first reserve review usually happens after one to three clean processing months. Chargeback ratio, refund rate and refund policy compliance all feed into whether the 5% to 10% reserve drops, holds steady, or moves to a rolling schedule. Ask at onboarding when your first review is scheduled.
- Business licence or articles of incorporation
- EIN confirmation letter
- Government ID for the signer
- 3 to 6 months of business bank statements
- 3 to 6 months of processing statements, if you have them
- Supplier documentation naming the manufacturer
- Product listings with lot-level COAs
- Screenshots of the marketing pages as they’ll appear at submission
Throughout, keep one habit: never describe your business differently to a processor than your website describes it. The file and the site have to match. When they don’t, the site wins and the account closes.
09 / GOOD QUESTIONS
Peptide payment processing questions.
Can peptide sellers get a merchant account?
+
Yes - with processors whose acquiring bank has an explicit peptide policy and a research-use framework. A peptide merchant account is underwritten by a bank that has agreed to board the category, not by a mainstream processor that will approve the application and close the account once the product mix becomes clear. The constraint isn’t whether it’s possible. It’s how many banks will price it, and what your site has to look like for them to say yes.
Why are peptides considered high risk?
+
End-use ambiguity. The same compound can be a laboratory reference material or an unapproved human drug, and underwriting can’t tell which one it’s boarding from the molecule alone. Add card-not-present ecommerce, elevated dispute rates in consumable categories, and a fast-moving regulatory picture, and the category lands in a high-risk bucket by default. Nobody at the processor is making a judgement about your business. They’re pricing uncertainty.
What rates should I expect for a peptide merchant account?
+
Most peptide placements land between 3% and 8.95% per transaction on cards, with ACH around 3.95% flat and a rolling reserve of 5% to 10% held for 90 to 180 days. Research-only sellers with lot-level documentation and a clean processing history sit near the bottom of that card range. Broader product mixes, injectables, higher tickets and international traffic push toward the top. Any quote under 3% for a peptide business is worth a hard second look.
What is a rolling reserve?
+
A rolling reserve is a percentage of your monthly volume that the processor holds back to cover future chargebacks, refunds and disputes. It’s released on a rolling basis after the hold period passes - so a 5% reserve held for 180 days means each month’s 5% comes back roughly six months later, provided the account stays clean. Most processors will review the percentage and the hold period after a stretch of clean processing.
What does RUO mean?
+
Research-use-only. It’s a labelling and intended-use convention stating the product is sold for laboratory research and not for human or veterinary use. For payments, RUO framing is what moves a file from drug-distribution risk to laboratory-supply risk - if the site, the product pages, the labelling and the checkout all support it consistently. A disclaimer on a page that also teaches dosing doesn’t establish an RUO position.
Do I need LegitScript certification?
+
It depends on the processor and the merchant category code you’re registered under. Certification is commonly required for pharmacy-shaped businesses and telehealth merchants, particularly under MCC 5912, and some processors extend that requirement to peptide sellers as their own policy. Others waive it for documented research-only sellers. Ask the processor directly, in writing, whether it’s required for your business and whether the application can proceed while certification is pending.
Can I sell injectable peptides?
+
Some processors will board them and many won’t - injectables are the fastest way to narrow the field. Injectables paired with syringes, needles and bacteriostatic water read as a consumer administration kit regardless of what the disclaimer says. If injectables are part of your catalogue, expect a smaller processor list, a higher rate, and a larger rolling reserve. Disclose the format up front; a file that discovers injectables during underwriting usually ends there.
What if I’ve been declined?
+
A decline isn’t a permanent mark, but it needs an explanation attached to it. Start by finding out why: was it the product mix, the marketing copy, the geography, or a bank with no peptide policy? Fix the cause before you apply again, and don’t shotgun applications across five processors at once. If a previous account was shut down or a reserve was held, disclose it. Processors price disclosed history. They decline discovered history. Our notes on what to do after a decline or shutdown are the place to start.
How long does approval take?
+
A complete application usually gets a decision in 3 to 10 business days. The variable is documentation - COAs, supplier paperwork, entity documents, bank and processing statements. Merchants who have the full pack ready sit at the fast end. Merchants who let underwriting chase paperwork sit at the slow end, and often get re-underwritten from scratch.
Can I use Stripe or PayPal?
+
Realistically, no - not for a peptide business at any scale. Mainstream processors prohibit or restrict the category in their terms, and the outcome is usually a frozen balance or an abrupt shutdown after a few months of processing rather than a clean decline at application. That’s worse than a decline, because it strands revenue mid-cycle and leaves a suspicious pattern on your account. Use them for nothing in this business, including a test transaction.
10 / NEXT STEP
Let’s find your processor.
Tell us about the business - product formats, end-use framing, geography, volume, ticket, processing history. We’ll come back with the processors that fit, tell you plainly when one doesn’t, and prep the documentation with you before anything goes to underwriting.
Peptides are one of several verticals we cover - browse the full list of high-risk payment processing industries.
Free to use · Team responds ASAP · We’re paid by the processor, not you.